News & articles
Avidity Biosciences Investor & Analyst Event: FORTITUDE™ Topline Data and Regulatory Updates for del-brax in FSHD
Avidity announced topline data in the del-brax program demonstrating consistent improvement across multiple functional measures compared to placebo. Data will be presented at the 32nd Annual FSHD Society International Research Congress (IRC) in Amsterdam. More...
FDA receives updates on data of the FORTITUDE-3 (del-brax) trial entering Phase 3
Novartis has discussed the FORTITUDE-3 del-prax Phase 3 trial design with the US Food and Drug Administration (FDA), sharing results from the trial to date and is extending the Phase 3 study to 36 months.
FSHD Europe’s PaLaDIn subcontract progressing well and on track
Six months into the PaLaDIn project, FSHD Europe’s contribution to Work Package 9 is progressing well and remains on track. Funded by the Innovative Health Initiative (IHI), PaLaDIn—Patient Lifestyle and Disease Data Interactium—is developing an Interactium®, a patient-centred real-world data platform for neuromuscular diseases (NMD).
FSHD Europe is supporting this work as a subcontractor through TREAT-NMD, alongside Work Package 9 lead FSHD Society. This work is aligned with Project Mercury in addressing an important challenge: as promising FSHD therapies move closer to approval, stronger health-economic evidence and robust disease-progression models will be essential to support timely reimbursement decisions and patient access.
FSHD Europe joins global call for stronger evidence on mortality in FSHD
FSHD Europe joins a global call for stronger population-level research to better understand mortality and life expectancy across FSHD and support the community.
FDA clears Phase 2 clinical trial of forazapadin for FSHD
Satellos Bioscience, a biotechnology company in Canada, has received clearance from the US Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its investigational medicine, forazapadin, in adults living with facioscapulohumeral muscular dystrophy (FSHD). The company has also announced a funding partnership with the FSHD Canada Foundation that could provide up to US$5 million to support the programme.
The trial is expected to begin later in 2026 and will evaluate the investigational therapy in adults living with FSHD.
FDA grants Fast Track designation to apitegromab for FSHD as Phase 2 FORGE trial begins dosing
2 September 2026 Scholar Rock’s investigational therapy, apitegromab, has received Fast Track and Orphan Drug designations from the US Food and Drug Administration (FDA) for facioscapulohumeral muscular dystrophy (FSHD). The company has also announced that the first...
FDA clears Phase 1 clinical trial of DYNE-302 for FSHD
FDA clearance allows Dyne Therapeutics to begin the first Phase 1 clinical trial of DYNE-302, an investigational therapy targeting DUX4 in FSHD.
Join Us!
We aim to be open and transparent in our approach and be respectful of cultural differences and the priorities of individual member organisations.








